Objective: Develop a dose-response curve for the effect of intranasal lidocaine on food intake. Design: Healthy obese subjects had food intake, ratings of hunger, desire to eat, craving and fullness measured at lunch after an overnight fast. Four treatments were given as nose drops (0.5-0.6 ml per nostril) 5 min before the meal in a double-blind manner with a four period crossover design including a 7-day washout between periods. The treatments were saline, 2.5, 10 and 25 mg lidocaine per nostril. The order of administration was randomly assigned to each subject. Electrocardiograms, vital signs, chemistry panels, complete blood counts (CBC) and nasal inspections were carried out before and after each dose. Subjects: Forty-seven subjects were screened, 34 were randomized and 20 subjects completed all four study periods in the trial. The subjects were 39712.5 (s.d) years of age, had a weight of 91713.0 kg, a height of 167710.3 cm, 56% were women, 47% were African-American and 53% were Caucasian. Measurements: Food intake, rating of hunger, desire to eat, craving and fullness are measures of efficacy. Adverse events, electrocardiograms, vital signs, chemistry panels, nasal inspections, CBC and physical exams are measures of safety. Results: The mean reduction in food intake vs saline control in the 20 subjects completing all four study periods was 3.377% (s.d), 4.278.5% and 7.477.3% in the 2.5 mg, 10 and 25 mg per nostril groups, respectively (P ¼ NS). Hunger and desire to eat in subjects who completed at least one study period decreased dose dependently (Po0.03, at the 25 mg per nostril dose). There were no clinically significant changes in safety measures, electrocardiograms, vital signs, chemistry panels, CBC or nasal inspections. Conclusion: Intranasal lidocaine reduced hunger and the desire to eat, but this did not translate into a significant reduction in food intake suggesting that intranasal lidocaine will not have value in treating obesity.
Introduction
An association between the sense of smell and appetite has been reported on many occasions. The sense of smell has been shown to increase appetite and food intake in restrained eaters [1] [2] [3] and, in case reports, people with a diminished sense of taste and smell have associated weight loss. 4, 5 In addition, the decline in weight with aging has been partially attributed to the normal age-related decline in the taste and smell senses, 6, 7 and patients with anorexia have been shown to have a diminished sense of smell. 8 Based on these reports, and the fact that women have been shown to have a significant weight loss that was maintained for 1 year, if they terminated eating when the taste and smell appeal of food dissipated, 9 we hypothesize that temporarily depressing the sense of smell before meals may be an effective strategy to decrease food intake. In addition, there are physiological correlates to these observations on smell and food intake that strengthen the importance of the association. The smell of food alone has been demonstrated to increase pancreatic polypeptide within 3 min and to increase colonic pressure. 10, 11 The sight and smell of food increase insulin secretion in the first 20 min, and this rise in insulin is blocked by atropine, suggesting that the rise is vagally mediated. 12 Lidocaine is a widely used topical anesthetic that is also used as a parenteral anti-arrhythmic agent. Lidocaine applied topically decreases sensation by altering the permeability of the nerve cells to sodium ions and inhibiting nerve activity caused by action potentials. Lidocaine applied topically gives peak anesthesia within 2-5 min that lasts for 30-45 min. 13 The maximal safe dosage for topical anesthesia in a 70 kg adult is 500 mg, and the intravenous infusion rate following a loading bolus of 50-100 mg is 72 mg in a 24-h period.
14 Doses of 25 mg per nostril a day were predicted to be well within the safe range for topical treatment. Three placebo-controlled pilot studies with one to four subjects were undertaken to determine whether intranasal administration of lidocaine (10 mg per nostril) would affect smell or, before meals, would have an acute effect on food intake (total kilocalories consumed).
Pilot study 1 Three male and one female subject between 23 and 60 years of age, with a body mass index (BMI) less than 25 kg/m 2 , participated in a study to determine the effect of intranasal lidocaine on smell. Subjects had 0.5 ml of 2% lidocaine (10 mg) or normal saline administered in both nostrils on two different days. The subjects were supine, with their head tilted back during the instillation. Five minutes after the instillation of the nasal drops, the subjects were blindfolded and a bottle of cinnamon, coffee or sand (the control condition) was gradually brought closer to the nose until the subject was able to identify the smell. The distance from the nose at which the smell was identified was recorded (starting distance ¼ 90 cm). The coffee, cinnamon or sand was then placed just under the nose and the intensity of the smell graded on a visual analog scale (VAS). After each testing material was put under the nose, the bottle was removed, the blindfold removed and the VAS completed before replacing the blindfold for the next test material. The difference in the VAS ratings of cinnamon and of coffee compared to sand ( ¼ DVAD) were multiplied by the distance ( ¼ DVAD Â d) from the nose that each smell was identified and compared by paired t-test. In addition, the VAS ratings for coffee and cinnamon just under the nose (DVAD) were compared to sand and analyzed by paired t-test.
The DVAD Â d for cinnamon was 32.6712.3 (s.e.m) and the DVAD Â d for coffee was 146.67165.2 (P ¼ NS). The DVAD for cinnamon was 20.578.4 (Po0.05) and the DVAD for coffee was 6.176.6 (P ¼ NS), respectively. Thus, there was a decrease in the sense of smell compared to the sand control as a consequence of intranasal lidocaine. It only reached statistical significance in this pilot study relative to the VAS rating of smell intensity just under the nose for cinnamon relative to sand. There was a decrease in the mean smell intensity for the ratings of VAS just under the nose of coffee and a decrease in smell when comparing smell intensity times distance from the nose the smell was identified for both cinnamon and coffee (NS).
Pilot study 2
The same three male and one female subject between 23 and 60 years of age, with a BMI less than 25 kg/m 2 , participated in a pilot study of food intake. The subjects presented to the food intake laboratory at noon after an overnight fast (except for water from 2100 the prior night) on two occasions a week apart. They had 0.5 ml of 2% lidocaine (10 mg) or 0.5 ml normal saline administered in each nostril while in a supine position with heads tilted back 20 min before presentation of a meal consisting of fried chicken pieces and water. They were allowed to eat and drink as much or as little as they wished over a 20-min period, and there were more chicken pieces than they could reasonably be expected to eat at one sitting. The order of administration of the lidocaine and saline was balanced, and the study was performed in a double-blind manner. The four subjects consumed 15%, 11%, 27% and 33% less food (g) after administration of lidocaine compared to placebo, The mean (s.d) reduction in food intake was 21.5720.4% (mean7s.d) which was statistically significant (Po0.02). In a similarly designed study, sibutramine, a drug approved for the treatment of obesity, gave a 12% decrease in food intake and an 8% weight loss at 6 months. 15, 16 If the acute food intake reduction observed for intranasal lidocaine has the same relationship to weight loss as sibutramine, intranasal lidocaine would be predicted to give a 14% loss of body weight at 6 months.
Pilot study 3
A healthy 53-year-old female subject with a BMI of 22 kg/m 2 with no sense of smell owing to trauma sustained many years prior in a motor vehicle accident had the same testing described in pilot study 2 between 0700 and 0800 after an overnight fast. Food intake was 6.4% less with the placebo than with 10 mg lidocaine. Lidocaine has been reported to reach the central nervous system with topical nasal application in rodents. 17 It was reasoned that if food intake seen in pilot study 2 were due to a central action of lidocaine, lidocaine would also be effective in a person with anosmia. This study of one anosmic subject suggests that the mechanism by which lidocaine decreases food intake is through a decrease in the sense of smell. These three pilot studies, taken with the literature reports of an association of the sense of smell with appetite, supported the undertaking of a larger placebo-controlled study to determine whether intranasal administration before meals has an acute effect on food intake.
Methods
Thirty-four healthy subjects 18 years of age or older with a BMI between 30 and 40 kg/m 2 and on no regular medications except contraceptives or hormone replacement therapy participated in this trial. At screening, subjects had a medical history, a physical examination including examination of the nasal mucosa, complete blood count (CBC) (hemoglobin, hematocrit, mean cell volume, platelet count, white
Intranasal lidocaine and food intake FL Greenway et al blood count, granulocyte number, neutrophil number, eosinophil number and basophil number), chemistry panel (glucose, creatinine, potassium, uric acid, albumin, calcium, magnesium, creatine phosphokinase, alanine leucine transaminase, alkaline phosphatase, iron, cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol), electrocardiogram, questionnaires to assess eating attitudes and behaviors, and urine pregnancy test for female subject. To control for the effects of the menstrual cycle on food intake, female subjects not on combined oral contraceptives who had a menstrual cycle completed their food intake tests in the luteal phase. Subjects who were pregnant, nursing a child, tobacco users, intolerant to lidocaine or were experiencing weight fluctuations of more than 5 kg, either up or down in the 3 months before the study, were excluded. Subjects with known thyroid disease, diabetes, hypertension, depression, psychiatric conditions or epilepsy were also excluded. Women of childbearing potential who were unwilling to use effective contraception or subjects or who had a restraint score greater than 13 on the Eating Inventory (EI) questionnaire 15 were excluded from participation. Those passing screening returned to the eating laboratory at lunchtime on four separate occasions to receive 0.5 ml of fluid in each nostril and to complete their food intake tests. Clinic staff performed the nasal application in order to minimize exposure to the posterior pharynx. Participants were instructed not to eat or drink anything except water for 12 h before each test meal. A meal of fried chicken pieces (Banquet Popcorn Chicken) in an amount larger than could reasonably be consumed was begun approximately 5 min after the nose drops were administered. The pieces of chicken were fried in a batter and cut into standard bite sized units (8 g ). The chicken was 2.32 kcal/g (9.71 kJ/g) and 43% kcal from fat, 17% kcal from protein and 40% kcal from carbohydrate. The participant was allowed to use a condiment sauce with the chicken. Participants were allowed to eat as much or as little as they wished. Laboratory staff recorded the duration (s) of the meal. Eating behavior was monitored by the weight of the food consumed. Subjects completed a set of VAS to measure appetite before the nose drops and before and after each meal. Questions to assess the subject's sensory perception of the chicken were administered after the nose drops were given, but before each meal. All subjects received saline, 2.5, 10 and 25 mg lidocaine per nostril in a balanced order and in a double-blind manner while in the supine position. These doses were from commercial lots of lidocaine and administered as 0.5 ml of fluid except for the 25 mg dose, which was given as 0.625 ml of fluid. The fluids for nasal administration were drawn from a new previously unopened vial. Blood pressure and pulse were taken before and after each lunch. Preceding each instillation of lidocaine or placebo and on the day following each lunch test, subjects had a brief physical exam with attention to inspection of the nasal mucosa, chemistry panel, electrocardiogram and CBC. On the last visit, a full physical examination was performed with attention to inspection of the nasal mucosa.
Food intake
Food intake was monitored using a Universal Eating Monitor (UEM). The UEM consists of a scale that is concealed in a table and connected to a computer, which automatically records the weight of food removed (eaten) from a plate on top of the scale. The table is covered with a tablecloth and the research participant is not acutely aware food intake is being monitored. The UEM records the cumulative amount of food consumed and the rate of food intake over time. In the present study, the UEM was used to record the amount (g and kcal) of food consumed.
Questionnaires
The EI assesses dietary restraint (the intent and ability to restrict caloric intake) and disinhibition (the tendency to overeat). The EI was administered at screening and people were excluded who scored above 13 on the dietary restraint scale. 15 The Taste/Cold Questionnaire was administered before each food intake test to assess if the participant was suffering from any conditions (e.g., cold) that might influence taste and food intake. If so, the test lunch was rescheduled. VAS, Appetite (Set 1) -VAS was used to assess subjective ratings of appetite (hunger, fullness and desire to eat) at each food intake test. VAS is a reliable and valid measure of subjective states related to food intake. 16 One additional question regarding food cravings was added to the previously validated VAS questions. Menstrual Cycle Interview -Menstrual Cycle Interview was developed to assess phase of the menstrual cycle for female subjects. Controlling for menstrual cycle in food intake studies is important because phase of cycle has been found to influence food intake.
Statistics
The food intake and VAS data were analyzed using least squares means estimated from a linear mixed effects model that included terms for period, dose level, period by dose level interaction and an unstructured covariance matrix to model correlations within subject across periods. The pairwise test of differences in least squares means was performed (lidocaine dose level vs saline). Adjusted P-value was based on Dunnet's test for multiple comparisons. The SAS statistical software version 8.1, Cary, NC was used for the statistical analysis.
Results
Forty-seven subjects were screened, 34 were randomized and 20 subjects completed all four study periods in the trial 
Food intake
The mean decrease in food intake as a percent relative to the saline control for all 20 subjects that completed all testing conditions was 3.377% (s.d), 4.278.5% and 7.477.3% in the 2.5, 10 and 25 mg per nostril groups, respectively (P ¼ NS). There was a trend, based on the subjects who completed at least one study period, toward a dose-response relationship for the reduction in food intake, protein intake and fat intake (P ¼ 0.1) that almost became statistically significant for carbohydrate intake (P ¼ 0.06) ( Table 2 ). When the mean decrease in food intake, based on subjects who completed at least one study period, was calculated relative to control for all subjects with the missing data imputed as the mean for the missing lidocaine dose group, the decrease in food intake was 4.476.9, 0.777.1 and 6.776.9%, respectively, for the 2.5, 10 and 25 mg per nostril group.
VAS Scales
Hunger, desire to eat and craving, based on the subjects who completed at least one study period, all decreased in a dosedependent manner compared to placebo (Pp0.02). This difference became statistically significant at the 25 mg dose of lidocaine per nostril for hunger and desire to eat (Pp0.03) and nearly so for craving (Pp0.06). Fullness was increased compared to placebo, but there was no dose-response relationship, and the difference was only statistically significant at the 2.5 mg per nostril dose (P ¼ 0.05) ( Table 3) .
Discussion
Pilot studies suggested that lidocaine given intranasally would decrease the sense of smell and that intranasal lidocaine would decrease food intake. A single anosmic Table 2 Food intake (kilocalories) and difference in food intake from placebo after different doses of intranasal lidocaine Variable (kcal) 2.5 mg 10 mg 25 mg P-value
Food intake difference 561.9 (58. 
Values represent the difference in least squares means (s.e.) from placebo. Pairwise comparisons to placebo from t-test, P-values adjusted for multiple comparisons using Dunnett's procedure. Intranasal lidocaine and food intake FL Greenway et al female subject did not experience a decrease in food intake to intranasal lidocaine suggesting that the decrease in food intake was due to the decrease in the sense of smell.
Encouraged by these pilot studies, a larger study using subjects as their own controls was undertaken to define a dose-response relationship of nasal lidocaine to the decrease in food intake. Despite the known relationship that a sense of smell has with appetite and the pilot study data showing a statistically and clinically significant decrease in food intake with intranasal lidocaine, the food intake testing in the group of 20 subjects who completed all study periods used as their own controls could not confirm a reduction in food intake of the magnitude seen in the pilot study. There was a trend, based on those subjects who completed at least one study visit, toward a dose-response relationship in the reduction of food intake, protein intake and fat intake (P ¼ 0.1) that almost became clinically significant for the reduction in carbohydrate intake (P ¼ 0.06). The VAS, based upon subjects who completed at least one study period, did show a dose-response relationship for intranasal lidocaine to decrease hunger, the desire to eat and craving that became statistically significant for hunger and the desire to eat at the 25 mg per nostril dose and almost statistically significant for craving at the 25 mg per nostril dose. This study was designed to inform a decision whether to proceed to developing intranasal lidocaine as an obesity pharmaceutical. An obesity pharmaceutical must give 5% more weight loss than a placebo in order to fulfill the Food and Drug Administration criteria for approval. This suggests that the concept of decreasing food intake and hunger by decreasing the sense of smell is valid, but is quantitatively insufficient to be clinically significant or have potential for approval as a prescription medication to treat obesity.
Sibutramine 15 mg gives an approximate 12% decrease in food intake and an approximate 8% decrease in body weight from baseline at 6 months. 18, 19 Had the pilot data been confirmed, one might have expected intranasal lidocaine to produce a 14% decrease in body weight at 6 months based on the 21.5% reduction in food intake in the pilot study. A 14% weight loss would have been greater than any presently available obesity medication. Despite the routine use of lidocaine for the insertion of nasogastric tubes and the presumed safety of lidocaine administered by the nasal route, a minor metabolite of lidocaine is xylidine. Lidocaine is metabolized through Ndealkylation to monoethylglycinexylidide and glycinexylidide. These metabolites are hydrolyzed to 2,6-xylidine which is 2,6 dimethlyaniline, and rats fed 2,6 dimethylaniline at 3000 ppm develop nasal carcinomas. 20 Thus, even if intranasal lidocaine were effective in decreasing food intake and causing a clinically significant weight loss, the chronic use of lidocaine, as would be needed for the treatment of obesity, would raise safety concerns. Dyclonine hydrochloride has similar topical anesthetic properties to lidocaine, but is not metabolized to aniline. Thus, had lidocaine have been effective in causing a clinically significant decrease in food intake, dyclonine would have been the topical anesthetic of choice for further development as an intranasal pharmaceutical for the treatment of obesity. A weight loss of 5-10% or more at 6 months has been judged to be clinically significant. 21 The weight loss predicted from a 7.4% decrease in food intake would be approximately 4.9% of body weight. This amount of weight loss is not clinically significant, even if it were to be statistically significant with a larger number of subjects, and would not give the 5% greater weight loss than placebo needed for approval as an obesity drug. Thus, intranasal topical anesthetics to decrease the sense of smell in this study appeared to be safe, but did not have sufficient weight loss potential for development as an approved pharmaceutical treatment for obesity.
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